A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This multi-center, open-label study will evaluate the safety, pharmacokinetics,
pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in
patients with acute myelogenous leukemia. In Part A, patients will receive multiple
escalating doses of RO5429083 intravenously. In Part B, patients will receive RO5429083 plus
up to 4 cycles of cytarabine (1000 mg/m2 iv daily for 5 consecutive days). Anticipated time
on study treatment is until disease progression or unacceptable toxicity occurs.